Variable | A. Response/tolerance analysis | B. Completer analysis |
|---|
OR | 95% CI | p | OR | 95% CI | p |
|---|
Female vs. male | 0.19 | 0.05; 0.62 | 0.009 | 0.25 | 0.06; 0.91 | 0.04 |
Diagnostic delay | 0.97 | 0.91; 1.03 | 0.41 | 0.98 | 0.90; 1.05 | 0.66 |
Modified MASES | 0.82 | 0.61; 1.05 | 0.14 | 0.77 | 0.56; 1.02 | 0.08 |
BASDAI | 1.24 | 0.91; 1.75 | 0.18 | 1.41 | 1.00; 2.08 | 0.06 |
BMI | 0.78 | 0.64; 0.92 | 0.008 | 0.82 | 0.66; 0.97 | 0.04 |
- A is the ASAS40 response in patients with available outcome at 1 year, patients having discontinued the first TNFi in the meantime being considered non-responders. B is the ASAS40 response in patients still treated with the first TNF inhibitor at 1 year. Patients with co-morbid fibromyalgia were excluded from both analyses. ASAS40 40% improvement according to the Assessment in SpondyloArthritis International Society criteria, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMI body mass index; CI confidence interval; MASES Maastricht Ankylosing Spondylitis Enthesitis Score, modification refers to the inclusion of the plantar fascia in the count, OR odds ratio
